Primary PFS and safety analyses of a randomized phase III study of carboplatin plus paclitaxel plus /- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150) Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Reck, M.; Socinski, M. A.; Cappuzzo, F.; Orlandi, F.; Stroyakovskii, D.; Nogami, N.; Rodriguez-Abreu, D.; Moro-Sibilot, D.; Thomas, C. A.; Barlesi, F.; Finley, G.; Kelsch, C.; Lee, A.; Coleman, S.; Shen, Y.; Kowanetz, M.; Lopez-Chavez, A.; Sandler, A.; Jotte, R.

authors

Publication Date

  • December 1, 2017

webpage

published in

category

start page

  • 31

end page

  • 31

volume

  • 28